16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis

Non-Hormonal Pharmacologic Therapies for Vasomotor Symptoms

For individuals with absolute contraindications to estrogen (e.g., breast cancer survivors, thromboembolic history) or those who decline hormones, several evidence-based non-hormonal alternatives exist:

Non-Hormonal Therapies for Vasomotor Symptoms (VMS)
├── First-in-Class Targeted Mechanism: Neurokinin 3 (NK3) Receptor Antagonist
│   └── Fezolinetant (Veozah 45 mg PO daily) ──> Directly blocks NKB on KNDy neurons
│       └── Non-hormonal, non-sedating; MANDATORY baseline & periodic LFT monitoring!
├── Serotonergic / Noradrenergic Neuromodulators
│   ├── Paroxetine mesylate (7.5 mg PO qhs) ──> Only FDA-approved SSRI for VMS
│   │   └── CONTRAINDICATED with Tamoxifen! (Potent CYP2D6 inhibitor blocks tamoxifen activation)
│   ├── Venlafaxine (37.5–75 mg PO daily - SNRI) ──> Preferred first-line for patients on Tamoxifen
│   └── Escitalopram (10–20 mg PO daily - SSRI)
└── Centrally Acting Neuroactive Agents
    ├── Gabapentin (300–900 mg PO at bedtime) ──> Excellent for nocturnal hot flashes & insomnia
    └── Clonidine (0.05–0.1 mg PO daily or transdermal patch - Alpha-2 adrenergic agonist)

• Fezolinetant (Veozah): A breakthrough, FDA-approved, non-hormonal Neurokinin 3 (NK3) receptor antagonist (45 mg PO once daily). By directly blocking neurokinin B binding on hypertrophied KNDy neurons in the hypothalamic thermoregulatory center, it restores normal set-point firing without any estrogenic activity.
  • Clinical Safety Imperative: Requires baseline liver function tests (ALT, AST, total bilirubin) prior to initiation, followed by routine monitoring at 3, 6, and 9 months. Contraindicated in severe renal impairment (eGFR <30 mL/min) or cirrhosis.
• SSRIs and SNRIs: Modulate central serotonin and norepinephrine levels, stabilizing the hypothalamic thermoregulatory center and reducing hot flash frequency by 50% to 65%.
  • Paroxetine: Paroxetine mesylate 7.5 mg daily is FDA-approved for VMS.
  • Tamoxifen Interaction Warning: Paroxetine and fluoxetine are potent CYP2D6 enzyme inhibitors that block the bioactivation of tamoxifen into its active therapeutic metabolite (endoxifen). Therefore, paroxetine and fluoxetine are strictly contraindicated in breast cancer patients taking tamoxifen. In these patients, Venlafaxine (an SNRI with minimal CYP2D6 inhibition) is the first-line non-hormonal agent of choice.
• Gabapentin: An anticonvulsant and neuropathic pain agent (300 to 900 mg taken orally at bedtime). Provides substantial reductions in hot flash severity and night sweats, making it particularly beneficial for women whose primary complaint is nocturnal awakenings and insomnia.

Postmenopausal Osteoporosis Prevention & Management

Postmenopausal osteoporosis is a skeletal disease characterized by low bone mass, microarchitectural deterioration of bone tissue, and compromised bone strength, leading to fragility fractures (vertebral compression, hip, and distal radius / Colles fractures).

Screening & Diagnostic Criteria (DEXA & T-Scores)

• Universal Screening: Bone Mineral Density (BMD) testing via Dual-Energy X-ray Absorptiometry (DEXA) is universally recommended for:
  • All postmenopausal women aged ≥65 years, regardless of clinical risk factors.
  • Postmenopausal women <65 years with clinical risk factors for fracture (e.g., low body weight <127 lbs, parental history of hip fracture, current smoking, chronic oral glucocorticoid therapy, rheumatoid arthritis, excessive alcohol intake), or whose 10-year major osteoporotic fracture risk on the FRAX tool meets the threshold equivalent to a 65-year-old woman with no additional risk factors (commonly cited as 8.4%; published estimates range from about 8.4% to 9.3% depending on the reference cohort).
• World Health Organization (WHO) T-Score Diagnostic Criteria:
  • Normal: T-score ≥ -1.0 SD (within 1 SD of a young adult reference mean).
  • Osteopenia (Low Bone Mass): T-score between -1.0 and -2.5 SD.
  • Osteoporosis: T-score ≤ -2.5 SD at the femoral neck, total hip, or lumbar spine; OR the occurrence of an adult fragility fracture (fall from standing height or less), regardless of T-score.

Non-Pharmacologic Foundation

• Calcium & Vitamin D: Total elemental calcium intake of 1,200 mg/day (optimally achieved through dietary sources; add calcium carbonate or calcium citrate supplements if diet is deficient). Vitamin D3 supplementation of 800 to 1,000 IU/day to maintain serum 25-hydroxyvitamin D levels ≥30 ng/mL.
• Lifestyle: Regular weight-bearing exercise (walking, jogging, dancing) and resistance/muscle-strengthening training; smoking cessation; limiting alcohol to <2 drinks/day; home fall-prevention assessments.

Pharmacologic Antiresorptive Therapy

• Oral Bisphosphonates (Alendronate 70 mg PO once weekly, Risedronate 35 mg weekly): First-line antiresorptive pharmacotherapy for diagnosed osteoporosis or high fracture risk (T-score ≤ -2.5 or FRAX 10-year hip fracture risk ≥3%). Bisphosphonates incorporate into the bone hydroxyapatite matrix and inhibit osteoclast farnesyl pyrophosphate synthase, inducing osteoclast apoptosis and halting bone resorption.
• Strict Oral Administration Instructions (Prevention of Chemical Pill Esophagitis):
  1. Take first thing in the morning upon arising with a full 8-ounce glass of plain water only (never juice, coffee, or mineral water).
  2. Take on an empty stomach at least 30 to 60 minutes before any food, beverage, or other medications (oral bioavailability is <1%).
  3. Must remain completely upright (sitting or standing) for at least 30 minutes (60 minutes for ibandronate) after swallowing the tablet; do NOT recline or lie down to prevent pill retention in the esophagus and severe chemical ulcerative esophagitis.
• Rare Long-Term Complications: Medication-related osteonecrosis of the jaw (ONJ) and atypical subtrochanteric femur fractures. Bisphosphonate "drug holidays" (temporary discontinuation after 3 to 5 years of stability in moderate-risk patients) are frequently considered to mitigate these risks.